scispace - formally typeset
M

Mary Beth Terry

Researcher at Columbia University

Publications -  478
Citations -  22790

Mary Beth Terry is an academic researcher from Columbia University. The author has contributed to research in topics: Breast cancer & Population. The author has an hindex of 73, co-authored 433 publications receiving 18942 citations. Previous affiliations of Mary Beth Terry include Columbia University Medical Center & University of North Carolina at Chapel Hill.

Papers
More filters
Journal ArticleDOI

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Karoline Kuchenbaecker, +67 more
- 20 Jun 2017 - 
TL;DR: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location, a large cohort study recruited in 1997-2011 provides estimates of cancer risk based on BRCA1 and BRCa2 mutation carrier status.
Journal ArticleDOI

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou, +396 more
- 02 Nov 2017 - 
TL;DR: A genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry finds that heritability of Breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome- wide average.
Journal ArticleDOI

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Nasim Mavaddat, +310 more
- 03 Jan 2019 - 
TL;DR: This PRS, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset is developed and empirically validated and is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.
Journal ArticleDOI

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Nasim Mavaddat, +132 more
- 01 Jan 2012 - 
TL;DR: Pathologic characteristics of BRCA1 and BRCa2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis.
Journal ArticleDOI

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Fergus J. Couch, +261 more
- 27 Mar 2013 - 
TL;DR: It is estimated that the breast cancer lifetime risks for the5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk, and the ovarian cancer lifetime risk is 63% or higher, based on the known cancer risk-modifying loci.